Stockscreener 앱 받기
26.01
4.16%
-1.13
시간 외 거래:
26.18
0.17
+0.65%
전일 마감가:
$27.14
열려 있는:
$26.42
하루 거래량:
10.06M
Relative Volume:
1.01
시가총액:
$10.12B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-2.9794
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
-3.06%
1개월 성능:
+4.04%
6개월 성능:
+5.24%
1년 성능:
-52.55%
1일 변동 폭
$25.68
$26.94
1주일 범위
$25.68
$28.48
52주 변동 폭
$23.15
$57.69
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.01 | 10.60B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Traders Purchase Large Volume of Call Options on Moderna (NASDAQ:MRNA) - MarketBeat
What to expect from Moderna Inc. in the next 30 days2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Vanguard Personalized Indexing Management LLC Acquires 11,609 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is a value investor pickMarket Trend Summary & Verified Technical Signals - Trung tâm Dự báo KTTV quốc gia
Moderna: More Downside In The Stock But The Cancer Vaccine Offers Potential (MRNA) - Seeking Alpha
Transcript : Moderna, Inc.Shareholder/Analyst Call - MarketScreener
Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination - MarketScreener
Moderna (MRNA) Reveals Promising Data from Cancer Study at ESMO 2025 - GuruFocus
Moderna (MRNA) Shares Decline After Reporting mRNA-4359 Results - GuruFocus
Moderna (MRNA) Shares Decline After Oncology Update - GuruFocus
Is Moderna Inc. stock cheap compared to fundamentalsForecast Cut & Advanced Technical Signal Analysis - Trung tâm Dự báo KTTV quốc gia
Goldman Sachs Trims Moderna Price Target to $34 From $35, Neutral Rating Kept - MarketScreener
Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025 - MSN
Q3 Earnings Estimate for Moderna Issued By Leerink Partnrs - MarketBeat
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Monroe Evening News
Moderna, Inc. (0QFD.XC) stock price, news, quote and history - Yahoo
Q3 2025 Results — Moderna to Report on Nov 6, 2025 with Live Webcast; Archived Replay Available - Stock Titan
Moderna Inc. Stock Advances 5.5%, Outperforms Peers - 富途牛牛
Moderna, Inc.Common Stock (NQ: MRNA - FinancialContent
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Moderna Might Be a One-Hit Wonder - The Globe and Mail
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
Intraday pattern recognizer results for Moderna Inc.Quarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
MRNA special meeting on non-exec option exchange, 2:1–5:1 ratios - Stock Titan
Leerink Partners Adjusts Price Target on Moderna to $16 From $15, Maintains Underperform Rating - MarketScreener
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Marion Star
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Moderna: Q3 Earnings PreviewI Fear A Halloween Horror Show (Downgrade) (NASDAQ:MRNA) - Seeking Alpha
Lobbying Update: $80,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks - GuruFocus
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Norwich Bulletin
How to use Fibonacci retracement on Moderna Inc.July 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Key facts: Moderna faces cash flow challenges; stock rises on therapy data - TradingView
Moderna (MRNA) Stock Trades Up, Here Is Why - The Globe and Mail
Moderna’s Off-The-Shelf Cancer Immunotherapy Shows Early Promise - insights.citeline.com
Is Moderna Inc. meeting your algorithmic filter criteriaRate Hike & Fast Exit Strategy with Risk Control - newser.com
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Benzinga
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment - GuruFocus
What’s next for Moderna Inc. stock priceJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Moderna (MRNA) Tops Healthcare Short Interest Rankings - GuruFocus
Respiratory Syncytial Virus (RSV) Market Explosion To hit - openPR.com
Moderna Claims Early Victory for Cancer Antigen in Melanoma - BioSpace
Moderna, Inc. (MRNA) Stock Analysis: Navigating Volatility With A 65% Potential Upside - DirectorsTalk Interviews
Moderna reports early cancer therapy data at medical conference - StreetInsider
KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC - MarketBeat
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress - Times Herald
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.50%
자본화:
|
볼륨(24시간):